Benlysta Belimumab Powder for Concentrate for Solution for Infusion

1. Indications and Usage
Systemic Lupus Erythematosus (SLE):
Used in combination with standard therapy for adult and pediatric patients (5 years and older) with active, autoantibody-positive SLE who have a high disease activity level (e.g., positive anti-dsDNA antibodies and low complement).
Active Lupus Nephritis (ALN):
Used in combination with standard therapy (corticosteroids plus cyclophosphamide or mycophenolate) for adult patients with active lupus nephritis.
2. Dosage and Administration
Route of Administration:
For Intravenous (IV) Infusion ONLY. Rapid IV injection is strictly prohibited.
Recommended Dosage:
SLE and ALN: 10 mg/kg administered at 0, 2, and 6 weeks, then every 4 weeks thereafter.
Duration: For SLE patients, consider discontinuing treatment if there is no improvement in disease control after 6 months of therapy.
Critical Administration Instructions:
Infusion Time: The infusion must be administered over at least 1 hour.
Preparation: Reconstitute using Sterile Water for Injection (final concentration 80 mg/mL). Gently rotate; do not shake.
Dilution: Dilute in 250 mL of 0.9% Sodium Chloride, 0.45% Sodium Chloride, or Lactated Ringer’s. Do not use Glucose Injection.
Pre-medication: Prophylactic administration of antihistamines (with or without antipyretics/analgesics) is recommended prior to infusion.
3. Mechanism of Action
BAFF Inhibition:
Belimumab is a recombinant human IgG1λ monoclonal antibody that selectively binds to and inhibits the activity of human B cell activating factor (BAFF, also known as BLyS).
B-Cell Modulation:
By neutralizing soluble BAFF, it prevents the differentiation and survival of autoreactive B cells, leading to a reduction in circulating B-cell subsets and immunoglobulin levels.
4. Safety and Warnings
Severe Hypersensitivity and Infusion Reactions:
Severe or life-threatening hypersensitivity and infusion reactions have been reported. Patients must be monitored for several hours after the first two infusions.
Infection Risk:
May increase the risk of serious infections. Do not use in patients with chronic or active infections.
Neuropsychiatric Events:
Increased risk of suicidal ideation and behavior has been observed.
Vaccination:
Live or attenuated vaccines should be avoided during treatment.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions:
Infusion-related reactions, nausea, insomnia, headache, pyrexia, nasopharyngitis, bronchitis, bronchospasm, and diarrhea.
Clinical Research Highlights:
Phase 3 trials (e.g., BELIEF, BLISS-LN) demonstrated that belimumab significantly improved disease activity response rates and reduced glucocorticoid requirements in SLE and ALN patients compared to placebo.
6. Drug Interactions
Immunosuppressants:
Concurrent use with other immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate) has not shown significant pharmacokinetic interactions.
Vaccines:
The immune response to vaccines may be altered; live vaccines are contraindicated.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Belimumab.
Appearance: White to off-white cake.
Packaging: Single-use vial (120 mg or 400 mg).
Storage: Store in the original carton at 2°C to 8°C. Do not freeze.